Royal Bank of Canada
SPRO icon

Royal Bank of Canada’s Spero Therapeutics SPRO Stock Holding History

Royal Bank of Canada’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4K Buy
+2,014
New +$5.27K ﹤0.01% 7008
2025
Q3 		– Sell
-5,739
Closed -$17K – 7500
2025
Q2 		$17K Buy
+5,739
New +$8.26K ﹤0.01% 6323
2024
Q3 		– Sell
-1,959
Closed -$3K – 7400
2024
Q2 		$3K Buy
+1,959
New +$2.96K ﹤0.01% 6675
2024
Q1 		– Sell
-315
Closed – – 7554
2023
Q4 		$0 Buy
315
+15
+5% +$18 ﹤0.01% 7551
2023
Q3 		$0 Buy
+300
New +$416 ﹤0.01% 7554
2022
Q4 		– Sell
-43
Closed – – 7684
2022
Q3 		$0 Buy
+43
New +$43 ﹤0.01% 7834
2022
Q2 		– Sell
-196,097
Closed -$1.71M – 7693
2022
Q1 		$1.71M Buy
196,097
+13,502
+7% +$138K ﹤0.01% 3199
2021
Q4 		$2.92M Buy
182,595
+2,493
+1% +$39.6K ﹤0.01% 2830
2021
Q3 		$3.32M Buy
180,102
+177,945
+8,250% +$2.86M ﹤0.01% 2635
2021
Q2 		$30K Buy
2,157
+96
+5% +$1.34K ﹤0.01% 6346
2021
Q1 		$30K Buy
2,061
+924
+81% +$16.3K ﹤0.01% 6200
2020
Q4 		$22K Buy
1,137
+510
+81% +$7.95K ﹤0.01% 6022
2020
Q3 		$7K Buy
627
+98
+19% +$1.16K ﹤0.01% 6051
2020
Q2 		$7K Sell
529
-49
-8% -$550 ﹤0.01% 5958
2020
Q1 		$5K Sell
578
-618
-52% -$5.45K ﹤0.01% 6050
2019
Q4 		$12K Buy
1,196
+896
+299% +$9.66K ﹤0.01% 6079
2019
Q3 		$3K Buy
300
+100
+50% +$1.05K ﹤0.01% 6219
2019
Q2 		$2K Hold
200
– – ﹤0.01% 6600
2019
Q1 		$3K Buy
200
+184
+1,150% +$1.95K ﹤0.01% 6445
2018
Q4 		$0 Sell
16
-122
-88% -$988 ﹤0.01% 7089
2018
Q3 		$1K Buy
138
+33
+31% +$383 ﹤0.01% 6620
2018
Q2 		$2K Buy
105
+103
+5,150% +$1.32K ﹤0.01% 6268
2018
Q1 		$0 Sell
2
-64
-97% -$776 ﹤0.01% 6758
2017
Q4 		$1K Buy
+66
New +$810 ﹤0.01% 6418

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada's SPRO Position: Q2 2026 in Review

Royal Bank of Canada opened a new position in Spero Therapeutics (SPRO) in Q2 2026: 2,014 shares worth $4K. The stake represents ﹤0.01% of the portfolio and ranks #7008 among its holdings. This is a return to the name: Royal Bank of Canada previously reported a position in SPRO as recently as Q2 2025.

Royal Bank of Canada first reported a position in SPRO in Q4 2017 and has held it in 24 quarters since. The position peaked at $3.32M in Q3 2021. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Royal Bank of Canada held 2,014 shares of Spero Therapeutics worth $4K as of Q2 2026.
  • Spero Therapeutics was a new Royal Bank of Canada position in Q2 2026.
  • Spero Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #7008 holding.
  • Royal Bank of Canada first reported a position in Spero Therapeutics in Q4 2017 and has held it in 24 quarters since.
  • Royal Bank of Canada's Spero Therapeutics position peaked at $3.32M in Q3 2021.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.